AR098854A1 - 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas - Google Patents
5-aril-1-imino-1-oxo-[1,2,4]tiadiazinasInfo
- Publication number
- AR098854A1 AR098854A1 ARP140104787A ARP140104787A AR098854A1 AR 098854 A1 AR098854 A1 AR 098854A1 AR P140104787 A ARP140104787 A AR P140104787A AR P140104787 A ARP140104787 A AR P140104787A AR 098854 A1 AR098854 A1 AR 098854A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- alkyl
- heteroaryl
- group
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente proporciona un compuesto que tiene actividad inhibidora de BACE1, su fabricación, composiciones farmacéuticas que los contienen y su uso como sustancias terapéuticamente activas. Los compuestos activos son útiles en el tratamiento terapéutico y/o profiláctico de, por ejemplo, la enfermedad de Alzheimer. BACE es una enzima escisora de APP en sitio b. Reivindicación 1: Un compuesto de fórmula (1), en la que R¹ se selecciona entre el grupo que consiste en i) alquilo C₁₋₆, y ii) halógeno-alquilo C₁₋₆; R² se selecciona entre el grupo que consiste en i) hidrógeno, ii) halógeno; iii) -NH-C(=O)-R⁴, iv) arilo, v) arilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre ciano, alquilo C₁₋₆, halógeno-alquilo C₁₋₆ y halógeno, vi) heteroarilo, vii) heteroarilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre R⁶, y viii) -CºC-R⁵; R³ es halógeno; R⁴ se selecciona entre el grupo que consiste en i) heteroarilo, y ii) heteroarilo opcionalmente sustituido por 1 - 3 sustituyentes seleccionados individualmente entre R⁶; R⁵ se selecciona entre el grupo que consiste en i) arilo, ii) arilo, heteroarilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre ciano, alquilo C₁₋₆, halógeno-alquilo C₁₋₆ y halógeno, iii) heteroarilo, y iv) heteroarilo, heteroarilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre ciano, alquilo C₁₋₆, halógeno-alquilo C₁₋₆ y halógeno; R⁶ se selecciona entre el grupo que consiste en i) ciano, ii) halógeno; iii) alquilo C₁₋₆, iv) halógeno-alquilo C₁₋₆, v) alquinilo C₂₋₆-O-, vi) heteroarilo, y vii) heteroarilo, heteroarilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre ciano, alquilo C₁₋₆, alcoxi C₁₋₆, halógeno-alquilo C₁₋₆, halógeno-alcoxi C₁₋₆ y halógeno; R⁷ se selecciona entre el grupo que consiste en i) halógeno, y ii) halógeno-alquilo C₁₋₆; m es 1 ó 2; n es 0 ó 1; y p es 0, 1 ó 2; o sales farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198700 | 2013-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098854A1 true AR098854A1 (es) | 2016-06-15 |
Family
ID=49876438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104787A AR098854A1 (es) | 2013-12-20 | 2014-12-19 | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9605006B2 (es) |
| EP (1) | EP3083644B1 (es) |
| JP (1) | JP6461162B2 (es) |
| KR (1) | KR102285306B1 (es) |
| CN (2) | CN105683199B (es) |
| AR (1) | AR098854A1 (es) |
| BR (1) | BR112016007430A2 (es) |
| CA (1) | CA2924022A1 (es) |
| HK (1) | HK1220204A1 (es) |
| MX (1) | MX365292B (es) |
| RU (1) | RU2016128365A (es) |
| TW (1) | TW201609754A (es) |
| WO (1) | WO2015091595A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016016061A (es) * | 2014-08-15 | 2017-03-10 | Hoffmann La Roche | 2,2,2-trifluoroetil-tiadiazinas. |
| JP6895424B2 (ja) * | 2015-08-12 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂａｃｅ１阻害剤 |
| CN114644566A (zh) * | 2020-12-21 | 2022-06-21 | 抚顺顺能化工有限公司 | 一种2-氨基-2-苯基丁酸的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5766198B2 (ja) * | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| US8404680B2 (en) * | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| US9067924B2 (en) * | 2011-03-04 | 2015-06-30 | Hoffmann-La Roche Inc. | 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors |
| US9221839B2 (en) * | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| EP2694521B1 (en) * | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| JP2014524472A (ja) * | 2011-08-22 | 2014-09-22 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用 |
| US9493484B2 (en) * | 2012-02-08 | 2016-11-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US9428476B2 (en) * | 2013-03-15 | 2016-08-30 | Merck Sharp & Dohme Corp. | S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use |
-
2014
- 2014-12-17 MX MX2016006906A patent/MX365292B/es active IP Right Grant
- 2014-12-17 US US15/105,725 patent/US9605006B2/en active Active
- 2014-12-17 KR KR1020167016040A patent/KR102285306B1/ko active IP Right Grant
- 2014-12-17 CN CN201480058595.4A patent/CN105683199B/zh not_active Expired - Fee Related
- 2014-12-17 JP JP2016541590A patent/JP6461162B2/ja not_active Expired - Fee Related
- 2014-12-17 EP EP14821587.4A patent/EP3083644B1/en not_active Not-in-force
- 2014-12-17 CN CN201810567706.4A patent/CN108690052A/zh active Pending
- 2014-12-17 CA CA2924022A patent/CA2924022A1/en not_active Abandoned
- 2014-12-17 WO PCT/EP2014/078133 patent/WO2015091595A1/en active Application Filing
- 2014-12-17 RU RU2016128365A patent/RU2016128365A/ru unknown
- 2014-12-17 BR BR112016007430A patent/BR112016007430A2/pt not_active Application Discontinuation
- 2014-12-19 TW TW103144659A patent/TW201609754A/zh unknown
- 2014-12-19 AR ARP140104787A patent/AR098854A1/es unknown
-
2016
- 2016-07-15 HK HK16108351.8A patent/HK1220204A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016007430A2 (pt) | 2017-08-01 |
| EP3083644B1 (en) | 2019-03-13 |
| EP3083644A1 (en) | 2016-10-26 |
| MX365292B (es) | 2019-05-29 |
| MX2016006906A (es) | 2016-08-17 |
| CN105683199A (zh) | 2016-06-15 |
| KR102285306B1 (ko) | 2021-08-04 |
| JP6461162B2 (ja) | 2019-01-30 |
| CN108690052A (zh) | 2018-10-23 |
| TW201609754A (zh) | 2016-03-16 |
| CN105683199B (zh) | 2018-06-26 |
| US9605006B2 (en) | 2017-03-28 |
| HK1220204A1 (zh) | 2017-04-28 |
| US20160318952A1 (en) | 2016-11-03 |
| WO2015091595A1 (en) | 2015-06-25 |
| RU2016128365A (ru) | 2018-01-25 |
| JP2017500344A (ja) | 2017-01-05 |
| CA2924022A1 (en) | 2015-06-25 |
| KR20160098263A (ko) | 2016-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR095347A1 (es) | Compuestos orgánicos | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| BR112012029647A2 (pt) | novos derivados de pirimidinas | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| AR098912A1 (es) | Inhibidores de syk | |
| ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
| EA201591455A1 (ru) | Производные бензимидазолона в качестве ингибиторов бромодомена | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| BR112014013974A8 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
| UY33950A (es) | Inhibidores de benzodioxano de la producciòn de leucotrieno | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| CO2017000980A2 (es) | Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a) | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |